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Abstract
The trioxacarcins are polyoxygenated, structurally complex natural products that potently inhibit
the growth of cultured human cancer cells. Here we describe syntheses of trioxacarcin A, DC-45-
A1, and structural analogs by latestage, stereoselective glycosylation reactions of fully
functionalized, differentially protected aglycon substrates. Key issues addressed in this work
include the identification of an appropriate means to activate and protect each of the two 2-
deoxysugar components, trioxacarcinose A and trioxacarcinose B, as well as a viable sequencing
of the glycosidic couplings. The convergent, component-based sequence we present allows for
rapid construction of structurally diverse, synthetic analogs that would be inaccessible by any
other means, in amounts required to support biological evaluation. Analogs arising from
modification of four of five modular components are assembled in 11 steps or fewer. The majority
of these are found to be active in antiproliferative assays using cultured human cancer cells.
The trioxacarcins are bacterial metabolites of remarkable structural complexity that broadly
inhibit the growth of cultured bacterial and eukaryotic cells.1–5 A number of unusual
chemical features characterize the family, including a rigid, highly oxygenated polycyclic
skeleton with a fused spiro epoxide function, as many as five ketal or hemiketal groups
(three of them within a span of four contiguous carbon atoms) and one or more unusual
glycosidic residues, eponymously identified as “trioxacarcinoses”. The most potent family
member yet identified, trioxacarcin A (Figure 1), displays subnanomolar IC70 values in a
number of different human cancer cell lines. Its extraordinary antiproliferative effects are
believed to derive from the fact that trioxacarcin A efficiently and irreversibly alkylates G
residues of duplex DNA, forming a covalent bond between the exocyclic carbon atom of the
spiro epoxide function and N7 of the G residue that is alkylated. Both the DNA lesion and
the product of depurination that is formed from it upon heating, a 1:1 adduct of guanine and
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ttrioxacarcin A (“gutingimycin”),6 have been crystallographically characterized in seminal
work from researchers at the University of Göttingen.7
Although so far as we are aware trioxacarcins have not been explored clinically in human
cancer therapy, a phase I study of a closely related natural product with a distinct
glycosylation pattern, LL-D49194α1 (Figure 1), was conducted in the early 1990s in 15
patients with diverse metastatic cancers that were refractory to existing therapies.8 While
one patient in this study with colon cancer responded with improvement in performance that
was sustained for 6 months, a fatality associated with cardiotoxicity led to suspension of the
trial. A retrospective analysis suggested that the murine models that were used to determine
dosing in the trial poorly predicted human pharmacokinetics; drug exposures ≥4-fold higher
than anticipated were observed in patients. These insights would no doubt inform future
clinical evaluations of trioxacarcins and their analogs, and suggest that one objective for
structural refinement of the class, were this feasible, would be to identify analogs with
diminished cardiotoxicity while retaining or enhancing antineoplastic effects. Structurally
modified trioxacarcins might also facilitate the preparation of antibody-drug conjugates
(ADCs), which are of considerable interest in light of a number of recent clinical successes
of ADCs in cancer therapy.9 Although at least one natural trioxacarcin is available by
fermentation (Maskey et al. reported the isolation of 257 mg of trioxacarcin A from 50 L of
culture broth),5 we believed that a fully synthetic approach would greatly expand the
number and diversity of trioxacarcins available for study beyond the relatively small pool of
structures accessible through semi-synthesis.3
At the onset of our studies in 2005 the development of a scalable, practical and easily
diversifiable synthetic route to molecules as complex as the trioxacarcins seemed an
insurmountably difficult challenge. Inspired by this challenge, and the potential impacts a
solution to the problem might have upon human medicine, we were led to embark upon a
careful retrosynthetic analysis. From this, three criteria emerged as necessary and sufficient
for a viable process: a practical solution must be modular, employing components of similar
synthetic complexity, as well as highly convergent and scalable (the latter criterion being
mitigated to some extent by the extraordinary potencies of the trioxacarcins). As an
important first step toward this end in 2011 we reported a six-step route to a differentially
protected trioxacarcin aglycon (“synthetic precursor 1” in Figure 1) by the assembly of three
components of similar complexity.10 We had anticipated that this precursor would serve
directly as a substrate for the introduction of carbohydrates such as trioxacarcinose B by
glycosylation of the hemiketal hydroxyl group at position C13 or, after cleavage of the p-
methoxybenzyl (PMB) ether protective group, would provide a substrate for selective
introduction of carbohydrates such as trioxacarcinose A by glycosidation of the hydroxyl
group liberated at position C4, which we expected to be more reactive. This expectation was
borne out in practice.
In the present work we establish an appropriate means to protect and glycosidic subunits
derived from trioxacarcinose A and trioxacarcinose B (Figure 1), to allow for their efficient
and stereocontrolled coupling to a fully functionalized aglycon core, as well as a viable
sequencing of the glycosylation reactions. Both carbohydrate subunits contain free hydroxyl
groups that lie in a 1,3-diaxial relationship with an α-anomeric linkage to the core, and the
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tissue of whether to protect these alcohols, and if so how, was of some concern, since it was
easy to imagine many protection schemes that would disfavor α-glycosylation through steric
interactions, but much less obvious how to promote the desired stereochemical outcome. We
were particularly concerned about the feasibility of forming the “trehalose” glycosidic
bond11 that links trioxacarcinose B to the sterically hindered and, we anticipated, poorly
reactive hemiketal function of the polycyclic core. As outlined in Results below, we learned
that in the case of coupling of trioxacarcinose A, protection of the 3-hydroxyl group was
unnecessary, whereas for successful coupling of trioxacarcinose B protection of the 3-
hydroxyl substituent was essential (protection of the tertiary alcohol function at position C4
was not required). We also learned that orthogonal modes of glycosidic activation were
necessary for the sequential glycosidic couplings leading to trioxacarcin A, and that the
ordering of the coupling reactions was critical. We also describe the modification of our
completed route to trioxacarcin A to prepare fully synthetic analogs that would not be
accessible by other means, and demonstrate that the majority of these analogs exhibit
antiproliferative activity in assays using cultured human cancer cells.
Results
To pursue glycosylation studies we first refined our existing route to the key synthetic
precursor 1,10 improving the efficiencies of both convergent coupling reactions (as detailed
in the Supplementary Information), and prepared 690 mg of this substance in
diastereomerically pure form in a single batch, a >10-fold scaling of our previously
published route. The 6-step sequence with current yields is briefly summarized in the first
part of Figure 4 below, which depicts the complete route to trioxacarcin A, and is
reproduced in order to facilitate discussion of analog synthesis later, where the structures of
the initial coupling components are varied.
We began our glycosylation studies by investigating the selective introduction of
trioxacarcinose A onto the C4-hydroxyl group of the diol substrate 2, formed in 83% yield
upon exposure of the synthetic precursor 1 to 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
(DDQ) in dichloromethane–water (Figure 2). The trioxacarcinose A residue is common to
many of the naturally occurring trioxacarcins, including the monoglycoside DC-45-A1, the
bisglycoside trioxacarcin A, and the trisglycoside LL-D49194α1 (Figure 1).12 We elected to
explore initial couplings with 1-O-acetyl trioxacarcinose A (3, Figure 2), which is available
in multi-gram amounts by a short and practical sequence.13 We found that when a mixture
of diol 2 (1 equiv), glycosyl donor 3 (2 equiv, a 1:12 mixture of α- and β-anomers,
respectively), and powdered 4-Å molecular sieves in dichloromethane at −40 °C was treated
with boron trifluoride etherate (1.0 equiv) as promoter the α-monoglycoside 4 was formed
in 79% yield (23 mg). The β-configured glycosylation product was not observed. Cleavage
of the tert-butyldimethylsilyl ether protecting group occurred upon exposure of the α-
monoglycoside 4 to an excess of triethylamine trihydrofluoride (30 equiv) in acetonitrile at
23 °C (16 h), affording DC-45-A1 in 76% yield after purification by RP-HPLC (4.6
mg). 1H- and 13C-NMR, FT-IR, and MS data from the synthetic material were in agreement
with values reported for the natural product.3 Definitive confirmation of identity was
achieved by comparison of our synthetic product with an authentic sample of DC-45-A1; the
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tsamples were indistinguishable spectroscopically and chromatographically (TLC co-spot,
RP-HPLC coinjection).
We next investigated the more challenging coupling chemistry that would enable formation
of the α-trehalose-type linkage between the polycyclic core of substrate 1 and a suitably
activated and protected trioxacarcinose B residue. Attempts to glycosidate substrate 1 with
trioxacarcinose B donors bearing a free 3-hydroxyl group were not successful, and so we
elected to protect the 3-hydroxyl function. In evaluating different protective groups, esters
were given priority because they were considered to minimize a potentially destabilizing
1,3-diaxial steric interaction with the nucleophile in the required α-glycosidic bond
formation. Because the trioxacarcinose A residue present in many natural trioxacarcins bears
an acetate ester we initially sought to use an ester group other than acetate for protection of
position C3 of the trioxacarcinose B donor, in order to avoid a problem of redundant
functionality. 4-Azidobutyryl seemed a well-differentiated ester protective group; to
evaluate it we first conducted a model study to explore conditions for its removal (Figure
3a). We observed that attempted deprotection of model substrate 1014 (hydrogenolysis in
ethanol at 23 °C using Pd/C and 1 atm H2, followed by brief heating of the intermediate 4-
aminobutyryl ester at 80 °C, to induce its cleavage) gave rise to a complex product mixture,
from which both the expected C3-alcohol (11) and its epimer (12) were isolated (Figure 3a).
The latter product was reasoned to have arisen from a retroaldol fragmentation-aldol
cyclization sequence. This result demonstrated that 4-azidobutyryl was unsuitable as a
protective group in the present context, and further suggested that the failure of our earlier
efforts to introduce trioxacarcinose B using donors with free 3-hydroxyl groups might have
been due to destruction of the sugar in paths initiated by (Lewis-acid promoted) retroaldol
fragmentation. We were therefore led to examine in detail whether differentiation of the 3-
hydroxyl group of trioxacarcinose B was actually required. A competition experiment
suggested that it was not (Figure 3b). 1H NMR analysis (500 MHz, CD3OD) of a 1:1:1
mixture of methyl α-3-O-acetyl trioxacarcinoside B (13), methyl α-trioxacarcinoside A (14),
and potassium carbonate showed that complete deprotection of the 3-O-acetyl protective
group of the trioxacarcinose B residue occurred within 2 h at 0 °C to give methyl α-
trioxacarcinoside B (15), while the acetate ester within the methyl α-trioxacarcinose A
residue was unaffected (Figure 3b). Retrospectively, it is easy to rationalize the much greater
stability of the α-trioxacarcinose A acetate ester toward methanolysis, for it is flanked on
both sides by methyl groups, whereas the 3-O-acetyl protective group of the trioxacarcinose
B residue has only one flanking methyl group.
With evidence that 1-O-acetyl-3-O-acetyl trioxacarcinose B (5) might provide a viable
donor en route to fully synthetic bisglycosides such as trioxacarcin A, we began to optimize
the conditions for coupling this activated sugar with the differentially protected synthetic
precursor 1 (Figure 2). We found that Lewis acids such as trimethylsilyl
trifluoromethanesulfonate (TMSOTf) and N-trimethylsilyl-
bis(trifluoromethanesulfonyl)imide (TMSNTf2)15 were preferred activating reagents. Over
the course of several experiments we determined that the highest yields of coupled product
were obtained when the ratio of glycosyl donor (5) to Lewis acid was ∼1.5:1. In an early
successful coupling we treated a suspension of crushed, activated 4-Å molecular sieves,
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tsubstrate 1 (1 equiv, 0.18 mM), and a large excess of donor 5 (30 equiv) in
dichloromethane–ether (3:1) at −78 °C with excess TMSOTf (20 equiv)16,17 and obtained
the α-glycoside 6 as the sole product in 78% yield after purification by RP-HPLC (30 mg,
“example 1” in the Supplementary Information). By increasing the concentration of
substrate 1 we could reduce the number of equivalents of donor 5 and Lewis acid that were
necessary to achieve full conversion (8.5 equiv 5, “example 2,” 58% yield, 120 mg; 5.0
equiv 5, “example 3,” 63% yield, 65 mg; both employing TMSNTf2 as Lewis acid; see
Supplementary Information). All attempts to couple substrate 1 with 3-O-acetyl
trioxacarcinose B donors containing alternative anomeric substituents, groups such as 1-
fluoro (α:β ∼ 1:3), 1-phenylthio (α:β ∼ 1:1.5), and 1-O-(4′-pentenyl) (α:β ∼ 1:1),14 were
unsuccessful under a wide range of conditions explored.
Deprotection of the trioxacarcinose B-coupled product 6 was achieved in three steps (Figure
2). First, methanolysis of the acetate ester of the trioxacarcinose B residue using potassium
carbonate as base afforded the alcohol 7 in 90% yield. Removal of the PMB ether protective
group (DDQ, 91% yield) gave the benzylic alcohol 8; subsequent cleavage of the tert-
butyldimethylsilyl ether group within this product (Et3N·3HF, 66% yield) then provided the
novel trioxacarcinose B monoglycoside 9 as a yellow-green foam after careful purification
by RP-HPLC.
With methods to couple (independently) both trioxacarcinoses A and B to polycyclic core
substrates, we sought to coordinate the two couplings in order to prepare the bisglycoside
trioxacarcin A. While in principle these transformations could be conducted in either
sequence, in practice, it proved necessary to conduct the more challenging glycosidation
with the trioxacarcinose B donor first, for when we attempted to glycosidate the
trioxacarcinose A-containing monoglycoside 4 (Figure 2) with the trioxacarcinose B donor 5
using TMSOTf as promoter (conditions found to be effective for glycosidation of substrate
1) we observed only products arising from cleavage of the existing α-glycosidic bond. To
investigate the alternative coupling sequence we first prepared the glycosyl acceptor 22 by
removing the PMB ether protective group within monoglycoside 6 (DDQ, 1.1 equiv, 95%
yield, Figure 4, middle). Attempted glycosylations of 22 with 1-O-acetyl trioxacarcinose A
as donor (3) using Lewis-acidic promoters such as TMSOTf or boron trifluoride–etherate
provided the desired α,α-bisglycoside 24 alongside a by-product in which the
trioxacarcinose B residue had been cleaved (i.e., the monoglycoside 4 depicted in Figure 2).
We therefore explored orthogonal activation conditions, and observed that addition of silver
hexafluorophosphate (6.0 equiv) to a mixture of substrate 22 (65 mg, 1 equiv), 1-
phenylthiotrioxacarcinoside A (23, 3.0 equiv, a 1:2.4 mixture of α- and β- anomers,
respectively), 2,6-di-tert-butyl-4-methylpyridine (8.0 equiv) and powdered 4-Å molecular
sieves in dichloromethane at 0 °C led to complete glycosylation within 1 h (Figure 4).18,19
The α,α-bisglycoside 24 was obtained as a greenish-yellow foam after purification by RP-
HPLC (58 mg, 74%).
Selective cleavage of the trioxacarcinose B acetate ester protective group occurred upon
exposure of the α,α-bisglycoside 24 to potassium carbonate for 1 h in ice-cold methanol
(higher temperatures led to decomposition). 1H NMR analysis of the yellow-orange residue
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tconfirmed that methanolysis of the trioxacarcinose B acetate ester had occurred cleanly, and
showed no evidence of any competing cleavage of the trioxacarcinose A acetate ester, as
anticipated from model studies (Figure 3b above). The product was not purified, but was
subjected to immediate deprotection with Et3N·3HF in acetonitrile at 23 °C (16 h). After
isolation by RP-HPLC pure trioxacarcin A was obtained as an orange-red powder (23 mg,
55% yield over two steps). Spectroscopic data (1H NMR, 13C NMR, FT-IR, CD, and MS)
were found to be identical with data we obtained from an authentic sample of natural
trioxacarcin A.4,20 We observed that trioxacarcin A, like its precursor 24, is unstable toward
base in alcoholic solvents; decomposition is evidenced by the formation of a deep burgundy-
red solution (solutions of pure trioxacarcin A in ethanol and chloroform are typically
orange).
Having established a modular 11-step sequence for the assembly of trioxacarcin A from 5
components of similar synthetic complexity (identified with circles in Figure 4) we next
sought to demonstrate the versatility of the sequence for the synthesis of analogs by
component variation. Deep-seated structural modifications were introduced by variation of
four of the five key building blocks (the cyanophthalide 17, the cyclohexenone 18, the
trioxacarcinose B donor 5, and the trioxcarcinose A donor 23); the synthetic sequence used
to prepare each analog was otherwise the same as the route to trioxacarcin A illustrated in
Figure 4 (experimental details are provided in the Supplementary Information). Figure 5
depicts 12 compounds representative of more than 30 analogs that we have prepared to date
by component variation. The analogs are depicted in a manner that highlights their structural
differences relative to trioxacarcin A, using color to trace the origins of the variations to the
components that were modified (identified in Figure 4). Below each structure in Figure 5 are
listed average GI50 values21 we obtained in growth-inhibitory assays using cultured H460
cells, a human lung cancer cell line that is known to be especially sensitive to trioxacarcin A
(we confirmed this, obtaining a GI50 value of 0.85 ± 0.36 nM for trioxacarcin A; DC-45-A1
was found to have a GI50 value of 37 ± 7nM—we are unaware of any previous
measurements of growth-inhibitory activity for this natural product in any cell line).5 Of the
12 analogs depicted in Figure 5, 10 were found to be sub-micromolar inhibitors of cancer
cell growth, a proportion that is representative of the larger pool of compounds synthesized.
A detailed discussion of structure-activity relationships is beyond the scope of the present
work, but it is evident that considerable structural variation around the polycyclic scaffold is
tolerated.
Discussion
Conformational and stereoelectronic arguments can be advanced to explain the high α-
selectivities observed in glycosylation reactions of trioxacarcinose A and B donors. We
believe that axial addition of the glycosyl acceptor to the oxocarbenium ion 36 is relatively
less impeded by 1,3-diaxial steric interactions than the alternative addition to the half-chair
conformer 37 (Figure 6). Conformer 36 is also favored stereoelectronically by virtue of its
axially disposed 3-acetoxy substituent.22–26 The stereochemical outcome of the
glycosylation reaction is not that expected if the 3-acetoxy group had participated, as often
occurs.27–28 A reviewer has suggested that this may be taken as evidence that the
stereochemistry of the glycosylation reaction is under thermodynamic control, which we do
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tnot dispute. Similar considerations apply to explain the highly α-selective couplings of
trioxacarcinose A donors 3 and 23. A remarkable and essential feature of glycosylation
reactions of both trioxacarcinose A and B donors is that they are compatible with the spiro
epoxide function of the many different core substrates containing it that we have examined.
Evidence suggests that the epoxy group efficiently alkylates only nucleophiles that benefit
from pi-stacking interactions with the aromatic core, such as a guanosine base of duplex
DNA.29
The synthetic sequence to trioxacarcin A we describe proceeds in 11 linear steps, four of
these convergent coupling reactions, and assembles five components of comparable
synthetic complexity: the cyanophthalide 17, the cyclohexenone 18, the epoxydiazodiketone
21, the trioxacarcinose A donor 23, and the trioxacarcinose B donor 5. Each of these
components has been synthesized by a short scalable sequence in multi-gram amounts. A
great virtue of the component-based assembly strategy that we have pursued both here and
elsewhere30 is that deep-seated structural modifications can be introduced and explored
relatively rapidly by independent modification of components, as illustrated by the subset of
structures presented in Figure 5. Simultaneous structural variation of more than one
component leads to multiplicative expansion of the pool of structures accessible for study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Trioxacarcin A and Structural Relatives
Trioxacarcin A, a complex bacterial metabolite with potent growth-inhibitory properties,
contains the unusual glycosidic residues trioxacarcinose A and trioxacarcinose B, whereas
the related natural product DC-45-A1 contains only the trioxacarcinose A residue.
Gutingimycin, also a bacterial isolate, is a covalent adduct of trioxacarcin A and guanine.
Other close relatives of the trioxacarcins with distinct glycosylation patterns are known, as
exemplified here by LL-D49194α1. In previous work in our laboratory, we prepared the
differentially protected synthetic precursor 1, which we anticipated would enable synthetic
access to the trioxacarcin class by selective, late-stage functionalization reactions.
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tFigure 2. Syntheses of DC-45-A1 and the trioxacarcinose B-containing monoglycoside 9
Stereoselective glycosylation reactions enabled preparation of monoglycosides containing
either trioxacarcinose A or B residues in sequences of three and four steps, respectively.
Importantly, both glycosidations preserve the spirocyclic epoxide function.
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tFigure 3. Model studies leading to selection of O-acetyl for protection of the 3-hydroxyl group of
trioxacarcinose B
a, Hydrogenolysis of methyl α-3-O-(4′-azidobutyryl)trioxacarcinoside B (10)14 followed by
brief heating produced a complex mixture containing both the desired product 11 and the
epimerized product 12. The latter product likely arose from a retroaldol fragmentation-aldol
cyclization sequence. b, Treatment of a mixture of methyl α-3-O-acetyl trioxacarcinoside B
(13) and methyl β-trioxacarcinoside A (14) with potassium carbonate in methanol-d4 led to
complete deprotection of the acetate ester of 13 within 2 h at 0 °C without affecting the more
hindered acetate ester of methyl β-trioxacarcinoside A (14). Complete deprotection of both
esters occurred upon prolonged stirring at 0 °C.
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tFigure 4. Modular synthesis of trioxacarcin A
An 11-step synthesis of trioxacarcin A was achieved by the convergent assembly of five
modular components of similar structural complexity, each denoted with a colored circle.
This strategy provides a general route to analogs with deep-seated structural variations.
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tFigure 5. Fully synthetic trioxacarcin analogs
We prepared non-natural trioxacarcin analogs by varying 4 of the 5 modular components
used in our synthesis of trioxacarcin A. Colored rectangles highlight structural differences
relative to trioxacarcin A. Each of the analogs pictured was prepared in 11 or fewer
chemical steps starting from modified modular components. The analogs prepared would be
difficult or impossible to obtain by semi-synthesis.
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tFigure 6. Rationalizations of the stereochemical outcome of glycosylation reactions with
trioxacarcinose A and B donors
Axial addition to the stereoelectronically favored half-chair 36 is relatively less impeded by
steric interactions than addition to the alternative conformer 37, offering one rationalization
for the high α-selectivities observed in glycosylation reactions of trioxacarcinose B donor 5
(see text for another). Similar considerations apply to explain the highly α-selective
couplings of trioxacarcinose A donors 3 and 23.
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